Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancies

NCT05154630 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT05154630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05154630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancies
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
January 14, 2022
Completion date
June 30, 2023
Enrollment
8 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced soft-tissue sarcoma